A pilot study on total body irradiation using TomoTherapy IMRT prior to hematopoietic stem cell transplantation

A pilot study on total body irradiation using TomoTherapy IMRT prior to hematopoietic stem cell transplantation - TomoTBI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033248

Enrollment

Registered

2018-07-03

Start date

2018-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic malignancy

Interventions

Irradiation using TomoTherapy Radixact Total Body Irradiation with 2Gy/fr, twice a day, 3 consecutive days 12Gy/6fr in total. At least 6 hours interval between the treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with hematopoietic malignancy who is scheduled to receive myeloablative conditioning using Total Body Irradiation (12Gy/6fr) for allogeneic stem cell transplantation 2. ECOG PS 0-2 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. General condition unfit for Total Body Irradiation 28days prior to registration. 2. Patient with active disease 3. Active other cancers 4. Unable to tolerate fixation during Total Body Irradiation 5. Unfit for TomoTherapy irradiation due to technical reasons 6. Patient during pregnancy 7. History of allogeneic or autologous transplantation 8. Other cases in which investigators considered unfit for this study

Design outcomes

Primary

Measure	Time frame
Frequency of Grade 3 or greater adverse events 3 months to 1 year following total body irradiation.	—

Countries

Japan

Contacts

Public ContactKazuteru Ohashi

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital Hematology Division

k.ohashi@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026